Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States

Journal of Medical Economics

Volumn 18, Issue 8, 2015, Pages 600-611

  Asche, Carl V ^a,b   Clay, Emilie ^c   Kharitonova, Elizaveta ^c   Zah, Vladimir ^d   Ruby, Jane ^e   Aballéa, Samuel ^c  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c CREATIV CEUTICAL   (France)

^d ZRX OUTCOMES RESEARCH INC   (Canada)

^e RECKITT BENCKISER   (United Kingdom)

Author keywords

Budget impact model; Buprenorphine naloxone; Healthcare expenditures; Medicaid

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; TABLET;

ADULT; ARTICLE; BUDGET; CAPITATION FEE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG FORMULATION; DRUG UTILIZATION; DRUG WITHDRAWAL; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL DISEASE; OPIATE ADDICTION; OUTPATIENT CARE; PATIENT MONITORING; PRESCRIPTION; SUBLINGUAL FILM FORMULATION; TABLET; TABLET FORMULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; ECONOMICS; HEALTH SERVICE; MARKOV CHAIN; OPIOID-RELATED DISORDERS; REPRODUCIBILITY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SUBLINGUAL DRUG ADMINISTRATION; TIME FACTOR; UTILIZATION;

ADMINISTRATION, SUBLINGUAL; ANALGESICS, OPIOID; BUPRENORPHINE, NALOXONE DRUG COMBINATION; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; MARKOV CHAINS; MEDICAID; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TABLETS; TIME FACTORS; UNITED STATES;

EID: 84964318529     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1036760     Document Type: Article

References (29)

1. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration 2004
2. Stoops WW, Hatton KW, Lofwall MR, et al. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl) 2010;212:193-203
3. Ling W, Mooney L, Hillhouse M. Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug Alcohol Rev 2011;30:300-5
4. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012;379:55-70
5. Gilson AM, Kreis PG. The burden of the nonmedical use of prescription opioid analgesics. Pain Med 2009;10(SUPPL. 2):S89-100
6. Hallinan R, Byrne A, Amin J, Dore GJ. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol 2005;20:1082-6
7. Jan SA. Patient perspective, complexities, and challenges in managed care. J Manag Care Pharm 2010;16(1 Suppl B):S22-5
8. Veilleux JC, Colvin PJ, Anderson J, et al. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010;30:155-66
9. White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005;11:469-79
10. United Nations Office on Drugs and Crime (UNODS), 2012. World Drug Report 2012. United Nations publication, Sales No. E.12.XI.1. http://www.un.org/en/hq/dpi/od.shtml
11. Centers for Disease Control and Prevention. Home and recreational safety: unintentional poisoning. Atlanta, GA: CDC, last updated 2 July 2013. Available at: http://www.cdc.gov/HomeandRecreationalSafety/Poisoning/index.html [Last accessed 27 June 2013]
12. Results from the 2009 National Survey on Drug Use and Health: Volume 1. Summary of National Findings. Available at: http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9Results.htm [Last accessed 10 November 2011]
13. Volkow ND, McLellan TA. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA 2011;305:1346-7
14. Bruneau J, Roy E, Arruda N, et al. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012;107:1318-27
15. Nicholls L, Bragaw L, Ruetsch C. Opioid dependence treatment and guidelines. J Manag Care Pharm 2010;16(1 Suppl B):S14-21
16. Chandwani HS, Strassels SA, Rascati KL, et al. Estimates of charges associated with emergency department and hospital inpatient care for opioid abuse-related events. J Pain Palliat Care Pharmacother 2013;27:206-13
17. Clark HW. Office-based practice and opioid-use disorders. N Engl J Med 2003;349:928-30
18. Lavonas EJ, Banner W, Bradt P, et al. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children. J Pediatrics 2013;163:1377-83
19. Lavonas EJ, Severtson SG, Martinez EM, et al. Abuse and diversion of bupre-norphine sublingual tablets and film. J Subst Abuse Treat 2014;47:27-34
20. Kharitonova E, Aballéa S, Clay E, et al. Analysis of persistence and healthcare costs in the US Medicaid population opioid-dependent patients treated with buprenorphine/naloxone film and tablet formulations. ISPOR 18th Annual International Conference, New Orleans, 18-22 May 2013
21. Clay E, Khemiri A, Zah V, et al. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence. J Med Econ 2014;17:626-36
22. Kharitonova E, Clay E, Ruby J, et al. Retrospective study of persistence and healthcare costs in the US opioid-dependent Medicaid population treated with buprenorphine/naloxone film and tablet formulations. ISPOR 18th Annual International Conference, New Orleans, 18-22 May 2013
23. Degenhardt L, Larney S, Randall D, et al. Causes of death in a cohort treated for opioid dependence between 1985 and 2005. Addiction 2014; 109:90-9
24. Office of the Legislative Counsel, Patient Protection and Affordable Care Act, ("PPACA"; Public Law 111-148) 2010
25. Truven Health Analytics. Medicaid Expansion: Profiling the Future Medicaid-Eligible Population. Truven Health Analytics, 2012
26. U.S. Department of health and human services, Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4856Findings). Rockville, MD. 2010
27. Clay E, Khemiri A, Ruby J, et al. Patient persistence with buprenorphine/naloxone film and tablet formulations in the treatment of opioid dependence in the United States: results from a 2010-2012 privately insured retrospective database. 15th International Society of Addiction Medicine Conference, Kuala Lumpur, 21-23 November 2013
28. Baser O, Chalk M, Fiellin DA, Gastfriend DR. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care 2011;17(SUPPL. 8): S235-48
29. Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009;104(6):982-92